Results 111 to 120 of about 270,350 (354)

Lower NT‐proBNP plasma concentrations in Pacific peoples with heart failure

ESC Heart Failure, EarlyView.
NT‐proBNP plasma concentrations were measured in participants of two NZ HF cohorts and were significantly lower in Pacific peoples and Māori compared with NZ Europeans. After accounting for age, sex, BMI, eGFR, LVEF and presence of AF, NT‐proBNP plasma concentrations remained significantly lower for Pacific peoples, but not for Māori.
Andree G. Pearson, John F. Pearson, Lynley K. Lewis, Allamanda Fa'atoese, Katrina K. Poppe, Chris Pemberton, Gerry Devlin, Mayanna Lund, A. Mark Richards, Richard Troughton, Robert N. Doughty   +10 more
wiley   +1 more source

Hypertrophic cardiomyopathy. [PDF]

, 1968
N. B. Karatzas, James Hamill, Peter Sleight   +2 more
openalex   +1 more source

Management of hypertrophic cardiomyopathy

Journal of Cardiovascular Medicine
Hypertrophic cardiomyopathy is an important cause of heart failure and arrhythmias, including sudden death, with a major impact on the healthcare system. Genetic causes and different phenotypes are now increasingly being identified for this condition.
Zhang, Yuhui, Adamo, Marianna, Zou, Changhong, Porcari, Aldostefano, Tomasoni, Daniela, Rossi, Maddalena, Merlo, Marco, Liu, Huihui, Wang, Jinxi, Zhou, Ping, Metra, Marco, Sinagra, Gianfranco, Zhang, Jian   +12 more
openaire   +4 more sources

Novel three‐dimensional ECG algorithm for reliable screening for cardiac amyloidosis

ESC Heart Failure, EarlyView.
The present manuscript describes the derivation and validation of an algorithm for screening of cardiac amyloidosis using 3‐dimensional ECG. The algorithm is based on a ECG vector loop, acquired over the duration of 15 seconds using 4 electrodes. With this easy to perform method, we describe a high diagnostic accuracy for the detection of cardiac ...
Amir A. Mahabadi, Jan Knobeloch, Viktoria Backmann, Lars Michel, Markus S. Anker, Reza Wakili, Christian Fach, Stefan D. Anker, Tienush Rassaf   +8 more
wiley   +1 more source

Identification of a novel titin-cap/telethonin mutation in a Portuguese family with hypertrophic cardiomyopathy

Revista Portuguesa de Cardiologia, 2020
Introduction and objectives: Hypertrophic cardiomyopathy (HCM) is a genetically and phenotypically heterogeneous disease; there is still a large proportion of patients with no identified disease-causing mutation.
Alexandra Toste, Andreas Perrot, Cemil Özcelik, Nuno Cardim   +3 more
doaj  

Multi‐microRNA diagnostic panel for heart failure with preserved ejection fraction in preclinical and clinical settings

ESC Heart Failure, EarlyView.
Abstract Aims Heart failure with preserved ejection fraction (HFpEF) is a complex syndrome accounting for half of heart failure cases. Although natriuretic peptides are the most accepted and extensively used biomarkers for heart failure, their diagnostic accuracy for HFpEF remains debatable.
Reza Parvan, Natale Rolim, Andreas B. Gevaert, Alessandro Cataliotti, Emeline M. van Craenenbroeck, Volker Adams, Ulrik Wisløff, Gustavo Jose Justo Silva, on behalf of the OptimEx Study Group   +8 more
wiley   +1 more source

Quantitative analysis of cardiac muscle cell disorganization in the ventricular septum of patients with hypertrophic cardiomyopathy. [PDF]

, 1979
Barry J. Maron, William C. Roberts
openalex   +1 more source

Identification, characterisation and outcomes of pre‐atrial fibrillation in heart failure with reduced ejection fraction

ESC Heart Failure, EarlyView.
Abstract Aims Atrial fibrillation (AF) in heart failure with reduced ejection fraction (HFrEF) has prognostic implications. Using a machine learning algorithm (FIND‐AF), we aimed to explore clinical events and the cardiac magnetic resonance (CMR) characteristics of the pre‐AF phenotype in HFrEF.
Anna Helbitz, Ramesh Nadarajah, Lan Mu, Harriet Larvin, Hesham Ismail, Ali Wahab, Patrick Thompson, Peter Harrison, Mohammad Harris, Tobin Joseph, Sven Plein, Mark Petrie, Marco Metra, Jianhua Wu, Peter Swoboda, Chris P. Gale   +15 more
wiley   +1 more source

Natural products targeting regulated cell deaths for adriamycin-induced cardiotoxicity

Cell Death Discovery
Adriamycin (ADR), as an anti-cancer drug in routine clinical application, is utilized to treat various cancers such as ovarian cancer, hematological malignant tumor, and endometrial carcinoma.
Zheng Wang, Yanli Zhu, Yu Yao, Wenyu Zhang, Bo Wang, Jing Wang, Yang Yang, Liwen Liu   +7 more
doaj   +1 more source

Atrial cardiomyopathy

ESC Heart Failure, Volume 12, Issue 2, Page 727-729, April 2025.
Wojciech Kosmala, Monika Przewłocka‐Kosmala   +1 more
wiley   +1 more source